Bruker Corporation (BRKR) has a MoatMap StockRank of 64/100 based on Quality (47/100), Value (26/100), and Momentum (74/100) factor scores. The current signal is HOLD. Bruker is a world leader in high-end life science tools and mass spectrometry. As biopharma companies outsource to CDMOs, the demand for validated, high-precision analytical instruments surges. Bruker possesses an un-copyable technological moat, high switching costs, and pricing power, making it an essential pick-and-shovel play on the CDMO and biotech innovation wave.
Bruker Corporation designs, manufactures, and markets high-performance scientific instruments and solutions vital for molecular and materials research, industrial analysis, and clinical diagnostics. The company's competitive moat is established through its highly specialized and advanced instrumentation, robust R&D capabilities, and extensive patent portfolio, which fosters deeply integrated relationships within the global scientific community. Bruker is a global leader in scientific instrumentation, particularly renowned for its expertise in mass spectrometry and magnetic resonance technologies.
| Price | $57.38 |
| Market Cap | $8.3B |
| P/E (Forward) | 24.88 |
| Price/Book | 3.73 |
| Return on Equity | -0.4% |
| Return on Invested Capital | 1.7% |
| Debt/Equity | 68.12 |
| Gross Margin | 47.6% |
| Operating Margin | 6.2% |
| Revenue Growth | 2.7% |
| Dividend Yield | 0.3% |
| Free Cash Flow | $212M |
Bruker Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).